Compositions and methods for ophthalmic and/or other applications
First Claim
1. A topical pharmaceutical composition for administration to an eye comprising a plurality of coated particles, each particle comprising:
- a core comprising a single pharmaceutical agent, wherein the pharmaceutical agent consists of loteprednol etabonate in an amount that is effective for treatment of a condition affecting an ocular surface, wherein the core is coated with a mucus penetration-enhancing coating comprising a (poly(ethylene oxide))-(poly(propylene oxide))-(poly(ethylene oxide)) triblock copolymer, wherein the poly(propylene oxide) block has a molecular weight of about 3600 Da, and the poly(ethylene oxide) blocks constitute about 70 wt % of the triblock copolymer; and
one or more ophthalmically acceptable carriers, additives, and/or diluents;
wherein the loteprednol etabonate is present in the topical pharmaceutical composition in an amount between about 0.1% and about 2% loteprednol etabonate by weight;
wherein the mucus penetration-enhancing coating is present in the topical pharmaceutical composition in an amount of between about 0.01% and about 2% by weight; and
wherein the mucus penetration-enhancing coating is present on the surface of the loteprednol etabonate at a density of at least about 0.01 molecules/nm2.
7 Assignments
0 Petitions
Accused Products
Abstract
Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
190 Citations
25 Claims
-
1. A topical pharmaceutical composition for administration to an eye comprising a plurality of coated particles, each particle comprising:
-
a core comprising a single pharmaceutical agent, wherein the pharmaceutical agent consists of loteprednol etabonate in an amount that is effective for treatment of a condition affecting an ocular surface, wherein the core is coated with a mucus penetration-enhancing coating comprising a (poly(ethylene oxide))-(poly(propylene oxide))-(poly(ethylene oxide)) triblock copolymer, wherein the poly(propylene oxide) block has a molecular weight of about 3600 Da, and the poly(ethylene oxide) blocks constitute about 70 wt % of the triblock copolymer; and one or more ophthalmically acceptable carriers, additives, and/or diluents; wherein the loteprednol etabonate is present in the topical pharmaceutical composition in an amount between about 0.1% and about 2% loteprednol etabonate by weight; wherein the mucus penetration-enhancing coating is present in the topical pharmaceutical composition in an amount of between about 0.01% and about 2% by weight; and wherein the mucus penetration-enhancing coating is present on the surface of the loteprednol etabonate at a density of at least about 0.01 molecules/nm2. - View Dependent Claims (4, 6, 8, 11, 13, 15, 16)
-
-
2. A method for treating inflammation, macular degeneration, macular edema, uveitis, dry eye, blepharitis, cystoid macular edema, and/or other disorder in an eye of a patient, comprising:
-
administering to an eye of the patient, a topical pharmaceutical composition comprising a plurality of coated particles, each particle comprising a core comprising a single pharmaceutical agent, wherein the pharmaceutical agent consists of an amount of loteprednol etabonate effective to treat a condition affecting an ocular surface, wherein the core is coated with a mucus penetration-enhancing coating comprising a (poly(ethylene oxide))-(poly(propylene oxide))-(poly(ethylene oxide)) triblock copolymer, wherein the poly(propylene oxide) block has a molecular weight of about 3600 Da, and the poly(ethylene oxide) blocks constitute about 70 wt % of the triblock copolymer; and one or more ophthalmically acceptable carriers, additives, and/or diluents; wherein the loteprednol etabonate is present in the topical pharmaceutical composition in an amount between about 0.1% and about 2% loteprednol etabonate by weight; and
,wherein the mucus penetration-enhancing coating is present in the topical pharmaceutical composition in an amount of between about 0.01% and about 2% by weight; and wherein the mucus penetration-enhancing coating is present on the surface of the loteprednol etabonate at a density of at least about 0.01 molecules/nm2. - View Dependent Claims (5, 7, 9, 10, 12, 14, 17, 18)
-
-
3. A method of making a composition for topical administration to the eye comprising a single pharmaceutical agent, wherein the pharmaceutical agent consists of loteprednol etabonate wherein the pharmaceutical agent is coated with a mucus penetration-enhancing coating comprising a (poly(ethylene oxide))-(poly(propylene oxide))-(poly(ethylene oxide)) triblock copolymer, wherein the poly(propylene oxide) block has a molecular weight of about 3600 Da, and the poly(ethylene oxide) blocks constitute about 70 wt % of the triblock copolymer forming a plurality of coated particles;
- and
one or more ophthalmically acceptable carriers, additives, and/or diluents, wherein the loteprednol etabonate is present in the topical pharmaceutical composition in an amount between about 0.1% and about 2% loteprednol etabonate by weight; wherein the mucus penetration-enhancing coating is present in the pharmaceutical composition in an amount of between about 0.01% and about 2% by weight, wherein the plurality of coated particles have an average smallest cross-sectional dimension of about 0.2 microns to about 0.3 microns; and wherein the mucus penetration-enhancing coating is present on the surface of the loteprednol etabonate at a density of at least about 0.01 molecules/nm2; the method comprising; milling a coarse aqueous suspension containing about 2-20% loteprednol etabonate in the form of coarse or micronized crystals, about 0.2-20% of the (poly(ethylene oxide))-(poly(propylene oxide))-(poly(ethylene oxide)) triblock copolymer, about 0.5-3% glycerin, about 0.1-1% sodium chloride, and about 0.001-0.1% EDTA in the presence of milling media to produce a nanosuspension of loteprednol etabonate particles sized in the range of about 200 nm to about 300 nm; separating the nanosuspension of loteprednol etabonate particles from the milling media; and mixing the nanosuspension of loteprednol etabonate particles with diluent. - View Dependent Claims (25)
- and
-
19. A topical pharmaceutical composition for administration to an eye comprising a plurality of coated particles, each particle comprising:
-
a core comprising a single pharmaceutical agent, wherein the pharmaceutical agent consists of loteprednol etabonate in an amount that is effective for treatment of a condition affecting an ocular surface, wherein the core is coated with a mucus penetration-enhancing coating comprising a (poly(ethylene oxide))-(poly(propylene oxide))-(poly(ethylene oxide)) triblock copolymer, wherein the poly(propylene oxide) block has a molecular weight of about 3600 Da, and the poly(ethylene oxide) blocks constitute about 70 wt % of the triblock copolymer; about 0.5% to about 1% glycerin; about 0.1% to about 1% sodium chloride; about 0.01% to about 0.1% disodium ethylenediaminetetraacetic acid; and about 0.01% to about 0.03% benzalkonium chloride; wherein the loteprednol etabonate is present in the topical pharmaceutical composition in an amount between about 0.1% and about 1% loteprednol etabonate by weight; and wherein the ratio of the weight of the loteprednol etabonate to the weight of the mucus penetration-enhancing coating is about 2;
1; andwherein the mucus penetration-enhancing coating is present on the surface of the loteprednol etabonate at a density of at least about 0.01 molecules/nm2. - View Dependent Claims (20, 21, 22, 23, 24)
-
Specification